Indiana University-Purdue University Indianapolis (IUPUI) / Non-alcoholic fatty liver disease and metabolic syndrome induced by high nutrient status have increasingly become a global health concern as it cause multiple complications. The mTOR complex is central in regulating anabolic reactions within cells under growth factors or under high nutrients stimulation. Constitutive and persistent activation of mTOR can impair cellular functions. In the first part of this study, we demonstrate a damping oscillation of mTOR activity during a long-term treatment of high fat diet. TFEB translocation and lysosomal enzyme activity also oscillate, but in an opposite direction. TFEB controls the lysosomal activity, autophagic degradation and lipid metabolism. Overexpression of wild type and mutant TFEB could inhibit NAFLD development in mice. In addition, TFEB location in nucleus inversely correlates with NAFLD severity in patients. mTOR activation under hypernutrition status suppresses TFEB translocation, inhibits lysosomal functions and autophagic degradation of lipid droplets. Inhibition of mTOR activity by rapamycin reverse the above phenotypes. Because mTOR activation also requires normal lysosomal function, the inhibition of TFEB by mTOR leads to decreased lysosomal function and mTOR downregulation. This negative feedback may explain the oscillation pattern of mTOR activation in long term high fat diet regimen and is a novel mechanism for inhibition of mTOR. In the second part of study, we report that Bid protein, previously known for its pro-apoptosis function in promoting mitochondrial permeability, plays an unexpected role in regulating fatty acid beta oxidation. Deletion of Bid in mice reprograms the body's response to hyper-nutrition caused by high fat diet, leading to the resistance to the development of obesity, liver steatosis and metabolic syndrome. These mice present a higher oxygen consumption, a lower respiratory quotient, and an increased beta-oxidation rate. Mechanistically, the high fat diet regimen triggers translocation of the full length Bid molecule to mitochondrial membrane. Genetic deletion of Bid also affects the stability of its binding protein, MTCH2 in the mitochondrial membrane. In summary, we describe in this study a mTOR-TFEB-lysosome feedback loop, which can regulate NAFLD development, and a novel Bid-mediated regulatory mechanism in beta-oxidation, which limits energy expenditure and promotes obesity development.

No description available.

Background: Liver cirrhosis is a global health problem and a national health problem in Egypt. There is a lack of literature on Health-Related Quality of Life (HRQOL) and symptoms experience of liver disease and cirrhotic patients in Middle East, particularly in Egypt. Aims: This PhD had three major aims: First aim: To describe HRQOL of Egyptian liver cirrhotic patients and to identify and evaluate the factors associated with (HRQOL) physical and mental health domains. Second aim: To explore and describe experienced symptoms (prevalence, severity and hindrance) in Egyptian cirrhotic patients and to identify and evaluate factors associated with symptoms severity and symptoms hindrance (distress). Third aim: To explore and describe how cirrhotic patients in Egypt perceive social support from spouse, family and friends and to identify and evaluate factors associated with general perceived social support. Method: A cross-sectional study with a convenience sample of 401 patients from three hospitals in Cairo, Egypt, was conducted between June and August 2011. Patients were interviewed to complete a background data sheet, Short Form-36v2 (SF-36), the Liver Disease Symptom Index (LDSI)-2.0 and the Multidimensional Scale of Perceived Social Support (MSPSS). Results: Findings for first aim: The findings showed that all domains and component summary scores [Physical component summary score (PCS) and mental component summary score (MCS)] of the generic SF-36 were below the norm (cut-off score 50), suggesting that patients with liver cirrhosis in Egypt have poor HRQOL. About 87.2% of the patients rated their general health as poor or fair, which means the majority of these patients have low perceived general health. Many socio-demographic and medial factors were shown to be significantly associated with perceived HRQOL. Women, illiterate and unemployed people, and patients with frequent hospitalisation had poor PCS and MCS, while patients with advanced disease stage, increasing number of comorbidities and complications and those admitted to inpatients had significantly poorer PCS only. Perceived social support from a spouse had a statistically significant positive association with PCS and MCS, while perceived social support from family and friends had a statistically significant positive association with MCS only. Also, severity and hindrance of symptoms significantly correlated with PCS and MCS. Using stepwise multiple linear regression analysis, two models were developed to identify factors associated with PCS (Model 1) and MCS (Model 2) health. Model 1 could significantly explain 19% of the variation in PCS (R2 = 0.190, R2adj = 0.180, p = 0.0005), and four factors (symptoms severity, disease stage, comorbidities and employment status) were significantly (p ≤ 0.02) associated with PCS. Model 2 could significantly explain 31.7% of the variation in MCS (R2 = 0.317, R2adj = 0.308, p = 0.0005), and four factors (symptoms severity, employment status, perceived spouse support and perceived family support) were associated (p ≤ 0.04) with MCS. The key findings of this study were that severity of symptoms and social support from spouse and family were associated with HRQOL. Where patients with high symptoms severity were likely to report poor PCS and MCS; and patients with low perceived social support were likely to report poor MCS. Symptoms severity contributed significantly in explaining 28.7% of the variation in PCS and 43.6% of the variation in MCS. Findings for second aim: This study found that the majority of patients had one or more of a wide range of symptoms and social problems. Two-thirds of patients reported joint pain (78.3%), decreased appetite (75.6%) and memory problems (77.3%). Joint pain and depression were reported to have the biggest impact on daily life. Symptoms severity and distress were significantly higher among patients who were: female, illiterate, unemployed, and who had advanced cirrhosis with more complications and comorbidities (p ≤ 0.006). Symptoms severity (r=-0.206) and symptoms distress (r=-0.205) were negatively associated with perceived social support (p=0.005). Stepwise regression analysis showed that the regression model could significantly explain 19.6% of the variation in symptoms severity (R2 = 0.196, R2adj = 0.180, p = 0.0005), and 14% of the variation in hindrance of symptoms (R2 = 0.140, R2adj = 0.132, p = 0.0005). Being female, having an increasing number of liver disease complications, and having low perceived support from spouse were significantly associated with high-perceived symptoms severity and hindrance (p≤0.01). Findings for third aim: This study found that social support score was relatively high among patients with cirrhosis in Egypt (total score mean of MSPSS was 2.02± standard deviation (0.537), while perceived support from spouse was the highest source of support. 67.5% of the patients felt their spouse is around when they need him/her and 71.7% of them share their joys and sorrows with their spouse. Likewise, 64.9% of married people feel their spouse cares about their feelings. In relation to the perception of adequacy of family support, it was observed that 52.6% felt that their families do not really try to help them. At the same time, 52.1% reported that they got the emotional help and support that they needed from their families. Regarding perceived support from friends, more than half of the patients reported that their friends do not really try to help them (57.9%), they cannot count on their friends when things go wrong (65.6%) and they cannot talk about their problems with their friends (56.4%). There was a significantly positive association between the perception of social support and general health perception (GHP), suggesting that when social support decreases GHP also decreases or and vice versa (r= 0.208, p = 0.0005). Stepwise regression analysis showed that the regression model could significantly explain 10.9% of the variation in perceived social support (R2 = 0.109, R2adj = 0.100, p = 0.0005). Marital status, gender, age and employment status were significantly associated with general perceived social support (p ≤ 0.01), while unmarried, females, unemployed and elderly cirrhotic patients were vulnerable groups that were likely to perceive low social support. Overall discussion and conclusion: This is the first study to investigate HRQOL, symptoms experience and perceived social support in patients with liver cirrhosis in Egypt. All aspects of HRQOL of Egyptian cirrhotic patients were poor, and they were experiencing various symptoms that can affect their daily life. However, social support was found to be related to perceived symptoms severity and perceived poor mental health. Hence, social support may alleviate suffering for certain cirrhotic patients. Nurses have a responsibility to assess and treat symptoms that cirrhotic patients experience, particularly such treatable symptoms as depression, pain and decreased appetite. Also, nurses should involve the patient’s family in any plan of care. Future intervention studies that aim to develop programs to relieve treatable symptoms and enhance social support are also recommended.

A doença hepática associada a sobrecarga de ferro pode ocorrer devido a causas genéticas ou secundárias. Esse estudo avaliou pacientes com hepatopatia crônica com sobrecarga de ferro submetidos à pesquisa das mutações HFE no período de 2007-2009 e classificou como portadores de hemocromatose hereditária HFE (HH-HFE) aqueles que apresentavam as mutações C282Y/C282Y ou C282Y/H63D e como sobrecarga de ferro não HFE aqueles que apresentavam outras mutações no gene HFE como C282Y/-, H63D/- e H63D/H63D ou pacientes sem qualquer uma dessas mutações mencionadas. Os objetivos do estudo foram 1) analisar e correlacionar os aspectos fenotípicos e genotípicos de grupo de indivíduos com doença hepática crônica e sobrecarga de ferro; 2) caracterizar o quadro clínico, laboratorial e anatomopatológico, em busca de achados compatíveis com o fenótipo de hemocromatose; 3) Correlacionar o quadro clínico com as mutações no gene HFE. Foram analisados 108 indivíduos portadores de hepatopatia crônica selecionados a partir de saturação de transferrina (ST) > 45% e ferritina sérica > 350 ng/mL. Foram estudados e comparados 16 pacientes no grupo HH-HFE com 92 no grupo sobrecarga de ferro não HFE. Da casuística geral, a idade média ao diagnóstico da doença foi de 46,69 anos (16-77), com 70,73% constituída por indivíduos de cor branca, 77,57% do sexo masculino e 64,8% tinham cirrose hepática. A frequência de cirrose hepática não diferiu entre os grupos, entretanto, artropatia, carcinoma hepatocelular, diabetes e osteoporose foram mais frequentes no grupo HH- HFE (53,8% x 15,9%, 31,2% x 7,06%, 56,2% x 30%, 72,7% x 32,1%, respectivamente, p < 0,05). Os pacientes com mutações HFE diagnósticas de HH apresentaram maior chance de ter carcinoma hepatocelular (OR= 5,0, p= 0,032) quando comparados com os portadores de outros genótipos HFE e aqueles sem mutação. Os níveis de ST, ferro e ferritina também foram maiores naquele grupo, bem como os graus de siderose 3 e 4 (p= 0,026). A ST foi a variável que se correlacionou independentemente com o diagnóstico das mutações C282Y/C282Y e C282Y/H63D. A frequência de fatores de risco para sobrecarga de ferro não diferiu entre os grupos. Observou-se, entretanto, que no grupo HH-HFE havia maior número de pacientes sem qualquer fator de risco detectado (p= 0,019). Níveis de ST > 82% apresentaram maior valor preditivo negativo para o diagnóstico de HH-HFE do que os de ferritina, ferro, capacidade total de ligação de ferro e de transferrina. Concluímos que os portadores de HH-HFE têm maiores graus de sobrecarga de ferro quando comparados ao grupo de sobrecarga de ferro não-HFE; em indivíduos com doença hepática crônica. ST > 82% tem maior acurácia para diagnóstico de HH-HFE; portadores de mutações C282Y em homozigose ou em heterozigose composta com H63D têm maior chance de apresentar carcinoma hepatocelular do que os portadores de outras mutações no gene HFE e pacientes sem mutação / Chronic liver disease related to iron overload may occur due to genetic or secondary causes. This study analyzed patients with chronic liver diseases and iron overload who were tested for HFE mutations from 2007 to 2009. Patients with C282Y/C282Y or C282Y/H63D mutations were diagnosed with HFE hereditary hemochromatosis (HFE-HH) and those with other HFE genotypes (C282Y/-, H63D/- or H63D/H63D) or individuals without HFE mutations (wild type) were designed as non-HFE iron overload. The aims of this study were: 1) to analyze and to establish correlations between phenotypic and genotypic aspects of individuals with chronic liver disease and with iron overload; 2) to charachterize the clinical manifestations, laboratory and histological findings consistent with the phenotype of hemochromatosis; 3) to verify associations between clinical manifestations and HFE mutations. One hundred and eight patients with chronic liver diseases and with iron overload, defined as transferrin saturation (TS) > 45% and serum ferritin levels > 350 ng/mL were included. Sixteen patients had HH-HFE and were compared with 92 patients with non-HFE iron overload group. The average of age at diagnosis was 46.69 years (16-77), 70.73% were Caucasians, 77.57% were male and 64.8% had hepatic cirrhosis. The proportion of hepatic cirrhosis was similar in both groups, nevertheless arthropathy, hepatocellular carcinoma, diabetes and osteoporosis were more frequent in the HFE-HH group (53,8% x 15,9%, 31,2% x 7,06%, 56,2% x 30%, 72,7% x 32,1%, respectively, p < 0,05). The HFE C282Y/C282Y or C282Y/ H63D genotypes had a higher chance to develop hepatocellular carcinoma (OR= 5.0, p= 0.032) when compared with the other HFE genotypes and with those wild type. The levels of TS, serum iron and ferritin were greater in HFE-HH group, as well as hepatic siderosis grade 3 and 4 (p= 0.026). TS was the biochemical marker of iron overload with the higher independent correlation with the presence of C282Y/C282Y and C282Y/H63D mutations. The frequency of risk factors for iron overload was not different between the groups, however, in HFE-HH group a greater number of patients without any risk factor was detected (p= 0.019). TS > 82% had a higher predictive negative value for diagnosing HFE-HH when compared to the levels of ferritin, serum iron, total iron binding capacity and transferrin. We concluded that the HFE-HH patients had a greater iron overload than patients with chronic liver diseases with non-HFE iron overload. TS > 82% had more accuracy to diagnose HFE-HH. The carriers of C282Y/C282Y or C282Y/H63D mutations had a higher probability to develop hepatocellular carcinoma, when compared to the patients with HFE genotypes and patients wild type

Diss. (sammanfattning) Linköping : Linköpings universitet, 2010. / Härtill 6 uppsatser.

Made available in DSpace on 2015-07-22T20:49:40Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-07-27 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Introdução: Pacientes com Hepatite C frequentemente tendem a produzir autoanticorpos. No teste fator antinúcleo em células HEp-2 (ANA-HEp-20), esses autoanticorpos geram diversos padrões de imunofluorescência, sendo o nuclear pontilhado fino o mais frequente deles. Recentemente, tem sido descrito um novo padrão de ANA-HEp-2 em pacientes com HCV, denominado padrão Rods e Rings (R&R), caracterizado por anéis e bastões. Objetivos: Avaliar as características clínicas, virológicas e padrão de resposta terapêutica dos pacientes que apresentam autoanticorpos que geram o padrão R&R, bem como proceder a uma avaliação preliminar dos aspectos celulares e moleculares desse novo sistema de autoantígenos. Métodos: Amostras de soro coletadas de 1998 até 2008 de 597 pacientes foram submetidas ao teste de ANA-HEp-2 em lâminas Euroimmun ou INOVA e classificados como R&R positivos quando apresentaram fluorescência sob forma de bastões de 3 a 10μm de comprimento e anéis de 2 a 5μm de diâmetro no citoplasma das células HEp-2. Entre os pacientes testados, 342 tinham HCV e 200 tinham outras doenças hepáticas crônicas ou autoimunes reumáticas, além de 55 pacientes co-infectados com HCV+HIV. As informações clínicas, virológicas e terapêuticas foram coletadas de bancos de dados atrelados às amostras de soro dos pacientes. Células HEp-2, 3T3 e MH22A foram cultivadas normalmente e/ou submetidas à tratamentos in vitro (tripsina e ribavirina) e com dois métodos alternativos de fixação, para estudo das estruturas do R&R por imunofluorescência indireta simples ou com técnicas de dupla-marcação com amostras R&R-positivas e anticorpos antitubulina-alfa e anti-CTP-sintase. Resultados: Dos 342 pacientes com HCV, 51 (15%) apresentaram o padrão R&R, enquanto que dos 200 pacientes com outras doenças hepáticas ou autoimunes, apenas um apresentou o padrão R&R (p<0.0001). Dos pacientes com HCV, 174 eram tratados e 168 não tratados. Dos 174 tratados, 49 (28%) apresentaram o padrão R&R contra apenas dois (1%) dos não tratados (p<0.0001). De 134 tratados e com informação adequada sobre a medicação utilizada, 108 tomavam interferon-α e ribavirina e 23 tomavam apenas interferon-α. Quarenta e um (38%) dos 103 que tomavam interferon-α e ribavirina apresentaram o padrão R&R contra nenhum (0%) dos 23 que tomavam apenas interferon-α (p= 0.0001). Quanto aos outros padrões de ANA-HEp-2, dos 23 pacientes que tomavam apenas interferon-α, 12 (52%) foram positivos enquanto apenas 27 (25%) dos que tomavam interferon-α e ribavirina foram positivos (p= 0.010). 9% dos pacientes co-infectados com HCV+HIV apresentaram o padrão R&R. Não encontramos relação entre a presença do padrão R&R e o genótipo do vírus, a carga viral e os dados demográficos dos pacientes com HCV. A porcentagem de respondedores ao tratamento foi ligeiramente menor nos pacientes que apresentaram o R&R, porem sem atingir nível de significância estatística (p=0,150). Lâminas ANA-HEp-2 de algumas marcas comerciais que não Euroimmun e INOVA e aquelas elaboradas no próprio laboratório não apresentaram as estruturas do R&R. Quando tratadas in vitro com ribavirina ou tripsina, as células HEp-2 ou 3T3 e MH22A de camundongo cultivadas expressaram vários anéis e bastões reconhecidos pelas amostras de soro R&R-positivas. Não observamos colocalização das estruturas R&R com microtúbulos e observamos fraca colocalização dos anéis e bastões com CTP-sintase. Conclusões: Autoanticorpos associados ao padrão R&R ocorreram em íntima associação ao uso de interferon-α e ribavirina em pacientes com hepatite HCV, independentemente de serem portadores do HIV. Não houve associação às características demográficas dos pacientes, ao perfil de resposta terapêutica, ao genótipo do HCV ou à carga viral. As estruturas em anéis e bastões associadas ao padrão R&R não ocorrem nas condições normais avaliadas, podendo ser induzidas in vitro pela exposição à ribavirina ou à tripsina. Há algum grau de conservação filogenética dos autoantígenos associados ao padrão R&R. Evidências preliminares indicam a presença da enzima CTP-sintase nas estruturas em anéis e bastões reconhecidas pelos autoanticorpos humanos. / Introduction: Patients with Hepatitis C frequently produce autoantibodies. In the antinuclear antibody assay on HEp-2 cells (ANA-HEp-2) these autoantibodies generate several immunofluorescence patterns, and the nuclear fine speckled pattern is the most common. A novel ANA-HEp-2 pattern has been recently reported, characterized by the presence of rods and rings in the cytoplasm. Objectives: To study the clinical and virological features, as well as the profile of therapeutic response of patients presenting autoantibodies generating the rods and rings (R&R) ANA-HEp-2 pattern and to perform a preliminary analysis of the cellular and molecular aspects of this novel autoantigen system. Methods: Serum samples obtained from 1988 to 2008 from 597 patients were processed in the ANA-HEp-2 assay on Euroimmun or INOVA slides and classified as R&R-positive when presenting immunofluorescence as 3-10μm long rods and 2-5μm diameter rings in the cytoplasm of HEp-2 cells. Among the tested patients, 342 had HCV, 200 had other chronic liver diseases or rheumatic autoimmune diseases, and 55 had HCV and HIV. Clinical, virological, and treatment information was obtained from the clinical data bank. Human HEp-2, and murine 3T3, and MH22A cell lines were cultured as usual and under special stimuli (exposure to trypsin or ribavirin), and prepared with alternative fixation protocols for processing in single or double indirect immunofluorescence with human anti-R&R serum and antibodies to tubulin and to CTP-synthase. Results: Among the 342 HCV patients, 51 (15%) presented the R&R pattern as opposed to only one among the 200 patients with other liver diseases and autoimmune rheumatic diseases (p<0.001). Among the HCV patients, 174 had been treated and 168 had received no treatment. Among the 174 treated patients, 49 (28%) presented the R&R pattern as opposed to only two (1%) of the 168 non-treated HCV patients (p<0.001). Among 134 HCV treated patients with detailed information on the treatment protocol, 108 used interferon-α and ribavirin and 23 used only interferon-α. Forty-one (38%) of the R&R pattern as opposed to none of the 23 patients receiving only interferon-α (p=0.0001). In contrast, 12 (52%) of the 23 patients receiving only interferon-α presented other non-R&R ANA-HEp-2 patterns as opposed to only 27 (25%) of the 108 patients under interferon-α and ribavirin (p=0.01). 9% of the patients with HCV and HIV presented the R&R pattern. There was no association between the occurrence of the R&R pattern and HCV genotype, viral load, and demographic features. The frequency of sustained virologic response was slightly lower in the R&R-positive patients but the difference did not reach statistical significance (p=0.15). ANA-HEp-2 slides from brands other than Euroimmun and INOVA, as well as in-house produced slides did not express the R&R structures. When treated in vitro with ribavirin or trypsin, HEp-2 cells and murine 3T3, and MH22A cell lines expressed prominent R&R structures recognized by human HCV serum samples. There was partial weak colocalization of CTP-synthase in the R&R structures but no colocalizadion of microtubule. Conclusions: autoantibodies associated with the R&R pattern were strongly associated with the use of interferon-α and ribavirin in patients with HCV, independently of co-infection with HIV. There was no association with demographic characteristics, the profile of therapeutic response, HCV genotype, and viral load. The rods and rings structures associated with the R&R pattern did not occur under normal conditions, but could be induced in vitro by exposure to ribavirin or trypsin. There is some degree of phylogenetic conservation of the autoantigens associated to the R&R pattern. Preliminary evidence indicates the presence of CTP-synthase in the cytoplasmic rods and rings structures recognized by human autoantibodies from HCV patients. / FAPESP: 2009/03796-5 / FAPESP: 2010/50710-6 / TEDE / BV UNIFESP: Teses e dissertações

A doença hepática associada a sobrecarga de ferro pode ocorrer devido a causas genéticas ou secundárias. Esse estudo avaliou pacientes com hepatopatia crônica com sobrecarga de ferro submetidos à pesquisa das mutações HFE no período de 2007-2009 e classificou como portadores de hemocromatose hereditária HFE (HH-HFE) aqueles que apresentavam as mutações C282Y/C282Y ou C282Y/H63D e como sobrecarga de ferro não HFE aqueles que apresentavam outras mutações no gene HFE como C282Y/-, H63D/- e H63D/H63D ou pacientes sem qualquer uma dessas mutações mencionadas. Os objetivos do estudo foram 1) analisar e correlacionar os aspectos fenotípicos e genotípicos de grupo de indivíduos com doença hepática crônica e sobrecarga de ferro; 2) caracterizar o quadro clínico, laboratorial e anatomopatológico, em busca de achados compatíveis com o fenótipo de hemocromatose; 3) Correlacionar o quadro clínico com as mutações no gene HFE. Foram analisados 108 indivíduos portadores de hepatopatia crônica selecionados a partir de saturação de transferrina (ST) > 45% e ferritina sérica > 350 ng/mL. Foram estudados e comparados 16 pacientes no grupo HH-HFE com 92 no grupo sobrecarga de ferro não HFE. Da casuística geral, a idade média ao diagnóstico da doença foi de 46,69 anos (16-77), com 70,73% constituída por indivíduos de cor branca, 77,57% do sexo masculino e 64,8% tinham cirrose hepática. A frequência de cirrose hepática não diferiu entre os grupos, entretanto, artropatia, carcinoma hepatocelular, diabetes e osteoporose foram mais frequentes no grupo HH- HFE (53,8% x 15,9%, 31,2% x 7,06%, 56,2% x 30%, 72,7% x 32,1%, respectivamente, p < 0,05). Os pacientes com mutações HFE diagnósticas de HH apresentaram maior chance de ter carcinoma hepatocelular (OR= 5,0, p= 0,032) quando comparados com os portadores de outros genótipos HFE e aqueles sem mutação. Os níveis de ST, ferro e ferritina também foram maiores naquele grupo, bem como os graus de siderose 3 e 4 (p= 0,026). A ST foi a variável que se correlacionou independentemente com o diagnóstico das mutações C282Y/C282Y e C282Y/H63D. A frequência de fatores de risco para sobrecarga de ferro não diferiu entre os grupos. Observou-se, entretanto, que no grupo HH-HFE havia maior número de pacientes sem qualquer fator de risco detectado (p= 0,019). Níveis de ST > 82% apresentaram maior valor preditivo negativo para o diagnóstico de HH-HFE do que os de ferritina, ferro, capacidade total de ligação de ferro e de transferrina. Concluímos que os portadores de HH-HFE têm maiores graus de sobrecarga de ferro quando comparados ao grupo de sobrecarga de ferro não-HFE; em indivíduos com doença hepática crônica. ST > 82% tem maior acurácia para diagnóstico de HH-HFE; portadores de mutações C282Y em homozigose ou em heterozigose composta com H63D têm maior chance de apresentar carcinoma hepatocelular do que os portadores de outras mutações no gene HFE e pacientes sem mutação / Chronic liver disease related to iron overload may occur due to genetic or secondary causes. This study analyzed patients with chronic liver diseases and iron overload who were tested for HFE mutations from 2007 to 2009. Patients with C282Y/C282Y or C282Y/H63D mutations were diagnosed with HFE hereditary hemochromatosis (HFE-HH) and those with other HFE genotypes (C282Y/-, H63D/- or H63D/H63D) or individuals without HFE mutations (wild type) were designed as non-HFE iron overload. The aims of this study were: 1) to analyze and to establish correlations between phenotypic and genotypic aspects of individuals with chronic liver disease and with iron overload; 2) to charachterize the clinical manifestations, laboratory and histological findings consistent with the phenotype of hemochromatosis; 3) to verify associations between clinical manifestations and HFE mutations. One hundred and eight patients with chronic liver diseases and with iron overload, defined as transferrin saturation (TS) > 45% and serum ferritin levels > 350 ng/mL were included. Sixteen patients had HH-HFE and were compared with 92 patients with non-HFE iron overload group. The average of age at diagnosis was 46.69 years (16-77), 70.73% were Caucasians, 77.57% were male and 64.8% had hepatic cirrhosis. The proportion of hepatic cirrhosis was similar in both groups, nevertheless arthropathy, hepatocellular carcinoma, diabetes and osteoporosis were more frequent in the HFE-HH group (53,8% x 15,9%, 31,2% x 7,06%, 56,2% x 30%, 72,7% x 32,1%, respectively, p < 0,05). The HFE C282Y/C282Y or C282Y/ H63D genotypes had a higher chance to develop hepatocellular carcinoma (OR= 5.0, p= 0.032) when compared with the other HFE genotypes and with those wild type. The levels of TS, serum iron and ferritin were greater in HFE-HH group, as well as hepatic siderosis grade 3 and 4 (p= 0.026). TS was the biochemical marker of iron overload with the higher independent correlation with the presence of C282Y/C282Y and C282Y/H63D mutations. The frequency of risk factors for iron overload was not different between the groups, however, in HFE-HH group a greater number of patients without any risk factor was detected (p= 0.019). TS > 82% had a higher predictive negative value for diagnosing HFE-HH when compared to the levels of ferritin, serum iron, total iron binding capacity and transferrin. We concluded that the HFE-HH patients had a greater iron overload than patients with chronic liver diseases with non-HFE iron overload. TS > 82% had more accuracy to diagnose HFE-HH. The carriers of C282Y/C282Y or C282Y/H63D mutations had a higher probability to develop hepatocellular carcinoma, when compared to the patients with HFE genotypes and patients wild type

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / This dissertation consists of an investigation on infectious canine hepatitis (IHC) and resulted in two scientific papers which are placed in the final part of this dissertation. The necropsy reports of 5,361 dogs necropsied over a 43-year period (1964-2006) were reviewed in search for cases of infectious canine hepatitis (ICH). Sixty two (1.2%) cases of the disease were found. Epidemiological, clinical and anatomopathogical data of these 62 cases are presented in the first paper. The second paper presents an immunoistochemistry (IHC) assay performed in the tissues of 27 dogs from the 62 cases surveyed in the first paper. Evaluated tissues by IHC included liver, kidney, spleen, lymph nodes, tonsils, lungs, small intestine, brain, and spinal cord. For each organ increasing degrees (from mild to marked) of intensity of immune staining were ascribed. The antigen of canine adenovirus type 1 was detected in most of evaluated organs, mainly in endothelial cells. / A presente dissertação consta de uma investigação sobre hepatite infecciosa canina e resultou na produção de dois trabalhos científicos que estão colocados ao final da dissertação. Os protocolos de necropsias realizadas em 5.361 cães durante um período de 43 anos (1964-2006) foram revisados em busca de casos de hepatite infecciosa canina (HIC) e sessenta e dois (1,2%) casos foram encontrados. Dados epidemiológicos, clínicos e anatomopatológicos desses 62 casos são apresentados e discutidos no primeiro trabalho. O segundo trabalho apresenta os resultados de um estudo imunoistoquímico (IHQ) realizado nos tecidos de 27 dos 62 cães pesquisados no primeiro trabalho. Os tecidos examinados incluíram fígado, rim, baço, linfonodos, tonsilas, pulmão, intestino delgado, encéfalo e medula óssea. Para cada órgão foram atribuídos graus crescentes (de leve a acentuada) de intensidade de imunomarcação. O antígeno de adenovírus canino tipo 1 foi marcado na maioria dos órgãos examinados, principalmente em células endoteliais.

La stéatose est la pathologie hépatique la plus répandue dans le monde, touchant environ 25 % de la population générale et jusqu’à 80 % des personnes en surpoids ou obèses. Cette maladie se traduisant par l’enrichissement des hépatocytes en triglycérides, est considérée comme bénigne. Cependant, environ 20 % des personnes atteintes de stéatose développent une stéatohépatite, pathologie caractérisée par une mort cellulaire et une inflammation et représentant un stade favorable au développement du carcinome hépatocellulaire. Les causes et mécanismes impliqués dans la progression de la stéatose vers la stéatohépatite sont encore à préciser. L’obésité, l’exposition aux contaminants environnementaux et la consommation d’alcool sont trois facteurs participant au développement des pathologies hépatiques. Pourtant, l’effet de l’interaction entre ces différents facteurs sur les pathologies hépatiques n’est pas connu. Dans ce contexte, cette thèse a eu pour objectif d’étudier l’impact d’une co-exposition au benzo[a]pyrène (B[a]P), un contaminant carcinogène environnemental, et à l’éthanol, utilisé à de faibles doses, sur les cellules hépatiques WIF-B9, présentant une stéatose préalable. Les résultats obtenus ont permis de démontrer qu’une telle exposition induit une progression de la stéatose hépatique vers un stade apparenté à une stéatohépatite, marquée par une augmentation de la mort cellulaire et de l’inflammation. Nous avons mis en évidence que la mort cellulaire résulterait de l’activation de p53 et d’une peroxydation lipidique. Une activation du récepteur aux hydrocarbures aromatiques et une production de monoxyde d’azote sont à l’origine de ces évènements via une modification du métabolisme de l’éthanol et du B[a]P conduisant à des dommages à l’ADN dépendants de la formation d’anion peroxynitrite. / Steatosis is the most common form of liver disease in the world, affecting around 25 % of the general population and up to 80 % of obese people. The disease is defined by the accumulation of triglycerides in hepatocytes and is generally considered as a benign condition. However, around 20 % of people with steatosis develop steatohepatitis, a disease characterized by cell death and inflammation, a condition that favors the development of hepatocellular carcinoma. The causes and mechanisms involved in the progression from steatosis to steatohepatitis are yet not fully understood. Obesity, exposure to environmental contaminants and alcohol consumption are three major factors contributing to the development of liver diseases. However, is still not yet clear what is the effect of the interaction between these different factors on liver diseases. In this context, the aim of this study was to evaluate the impact of a co-exposure to benzo[a]pyrene (B[a]P), an environmental carcinogenic contaminant, and ethanol, used at low doses, in WIF-B9 hepatic cell line, with a prior steatosis . The results demonstrate that this type of co-exposition induces a progression of hepatic steatosis to a steatohepatitis-like stage, marked by an increased cell death and an inflammation. We have shown that in this condition, cell death results from the activation of p53 and lipid peroxidation. Activation of the aromatic hydrocarbon receptor and production of nitric oxide are the origin of these events by a modification of both ethanol and B[a]P metabolism leading to peroxynitrite-dependent DNA damage.

A young man receiving high dose cytosine arabinoside (3g/m2 every 12 hours) for promyelocytic leukemia developed rapidly increasing hyperbilirubinemia and hepatorenal syndrome. The patient had been treated previously with courses of standard dose cytosine arabinoside without hepatic or renal complications. His condition rapidly deteriorated, and he required hemodialysis. The total bilirubin increased to 45.4 mg/dL, but alkaline phosphatase remained normal. Twelve days after starting chemotherapy, the patient died of hepatorenal failure. Liver necropsy revealed mild bile stasis and microvesicular steatosis. We suspect high dose cytosine arabinoside played a major role in causing impairment of bilirubin transport within the hepatocyte in this patient.